Telehealth company Hims & Hers Health Inc. said late Monday it is in “active discussions” with Denmark’s Novo Nordisk A/S to ...

Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues ...

Pfizer filed an antitrust lawsuit on Monday accusing Danish drugmaker Novo Nordisk of structuring its $9 billion bid for ...

The Wegovy-maker will release its third-quarter results on Wednesday, Doustdar’s first since taking charge in August with the ...

Novo Nordisk NVO is scheduled to report its third-quarter 2025 results before the opening bell on Nov. 5, 2025. The Zacks ...

Novo Holdings, which controls obesity drugmaker Novo Nordisk, is sharpening its focus on India, targeting single-specialty ...

Shares of Hims & Hers Health ($HIMS) rallied in pre-market hours on Tuesday after management said it’s in discussions with ...

Hims & Hers continues to sell compounded semaglutide, the active ingredient in Novo’s Wegovy and Ozempic drugs, and these ...

Hims & Hers said that the discussions with Novo Nordisk (DK:NOVO.B) are ongoing, that "no definitive agreement" has been reached, and that the two companies may not reach one. Nonetheless, Hims & Hers ...

Hims and Hers Health surpassed third-quarter revenue expectations, driven by subscriber growth and expanded personalized ...

Denmark's Novo Nordisk said on Monday it is confident that its proposed takeover of U.S. drugmaker Metsera does not raise any antitrust issues.